MultiPulse Therapy™ (MPT™) achieved 71% termination of acute, induced atrial fibrillation (AF) episodes at energy levels deemed to be tolerable for patients1,2 MINNEAPOLIS–(BUSINESS WIRE)–Cardialen, Inc., has published a first-in-human study in the Journal of the American College of Cardiology: Clinical Electrophysiology titled Novel Low-Voltage MultiPulse Therapy to Terminate Atrial Fibrillation. The study […]
Rhythm
EP Lab Digest Features Physician Experience with BioSig’s Cardiac Signal Acquisition Technology
Westport, CT, April 08, 2021 (GLOBE NEWSWIRE) — Leading industry publication highlights the rising importance of intracardiac signals in complex cardiac ablations that treat irregular heart rhythm disorders High-quality intracardiac signals are deemed essential to determine ablation endpoints PURE EP™’s signals are described as ‘indispensable’ by the physician user BioSig […]
Broward Health Medical Center Becomes First Hospital in Florida to Adopt Advanced Genesis Robotic Technology to Treat Heart Rhythm Disorders
ST. LOUIS, April 07, 2021 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that Broward Health Medical Center is establishing a robotic electrophysiology program to expand access to advanced minimally-invasive treatment of heart rhythm disorders in Florida. Broward Health Medical […]
New Real-World Observational Analysis of UPTRAVI® (selexipag) Underscores the Importance of Risk Assessment for Treating Pulmonary Arterial Hypertension (PAH) Patients
Data from the SPHERE Registry published in the Journal of Heart and Lung Transplantation SOUTH SAN FRANCISCO, Calif., April 6, 2021 /PRNewswire/ — Findings from an analysis of the first 500 patients enrolled in the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry) found more than three-quarters (76%) of pulmonary arterial hypertension (PAH) patients […]
Acutus Medical Initiates First IDE Therapy Trial with the AcQBlate® FORCE Sensing Ablation System
CARLSBAD, Calif., April 05, 2021 (GLOBE NEWSWIRE) — Acutus Medical (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced initial US enrollments in the company’s AcQForce™ Flutter Investigational Device Exemption (IDE) clinical trial. This trial is expected to enroll up […]
Cardiac Insight Reports Increased Cardea 20/20 ECG™ Sales to Screen Young Athletes for Conditions at Risk for Sudden Cardiac Arrest
Increased diagnostic precautions for athletes to detect cardiac conditions tied to sudden cardiac arrest amplified due to long-term COVID-19 cardiac risk concerns BELLEVUE, Wash.–(BUSINESS WIRE)–Cardiac Insight, Inc., a healthcare innovator specializing in wearable electrocardiogram (ECG) cardiac sensors and proven automated ECG analysis that delivers innovative solutions and highly differentiated benefits […]
Milestone Pharmaceuticals Announces First Patient Enrolled in the ReVeRA Study, its Phase 2 Trial of Etripamil in Atrial Fibrillation and Rapid Ventricular Rate
MONTREAL and CHARLOTTE, N.C., March 29, 2021 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the first patient has been enrolled in its Phase 2 proof-of-concept study of etripamil nasal spray for the Reduction of Ventricular Rate in patients experiencing Atrial fibrillation and rapid ventricular rate (AFib-RVR), […]
BioSig Awarded U.S. Patent Claims for the Noise-Filtering Methods for its Signal Processing Technology
Westport, CT, March 30, 2021 (GLOBE NEWSWIRE) — Claims address computer-implemented systems and methods for filtering noise from input cardiac signals using its PURE EP™ technology designed to elevate treatments for cardiac arrhythmias Atrial fibrillation is the most common arrhythmia type, affecting over 6 million people in the U.S. and causing […]
Bayer Announces Publication of Phase IV Adempas® (riociguat) Data in The Lancet Respiratory Medicine
The prospective, randomized, controlled, open-label study, which included outcomes from 226 patients with pulmonary arterial hypertension (PAH) (WHO Group 1), met its primary endpoint WHIPPANY, N.J.–(BUSINESS WIRE)–Bayer today announced that The Lancet Respiratory Medicine has published results from the Phase IV REPLACE (Riociguat rEplacing PDE-5i therapy evaLuated Against Continued PDE-5i thErapy) study in which intermediate-risk adult […]
Owlet’s Data Identifies Previously Undetected Increased Prevalence of Cardiac Arrhythmia in Young Infants in Study Published in The Journal of Pediatrics
Owlet algorithms detect tachyarrhythmia among infants at higher incidence than previously reported in studies relying on clinical diagnosis LEHI, Utah–(BUSINESS WIRE)–Owlet Baby Care Inc. announced today that a third-party study using data collected by its flagship product, the Owlet Smart Sock, identified that abnormally high heart rates – a condition known […]



